1167.HK
JACOBIO-B
HK$4.90
+4.70%
2026-05-29
About JACOBIO-B
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
Key Fundamentals
Forward P/E
-76.92
EPS (TTM)
HK$-0.22
ROE
-17.2%
Revenue Growth (YoY)
-95.0%
Profit Margin
-272.7%
Debt/Equity
21.43
Price/Book
4.32
Beta
0.38
Market Cap
HK$3.84B
Avg Volume (10D)
2.4M
Recent Breakout Signals
No recent breakout signals detected for 1167.HK.
Recent Price Range (60 Days)
60D High
HK$8.28
60D Low
HK$4.65
Avg Volume
3.2M
Latest Close
HK$4.90
Get breakout alerts for 1167.HK
Sign up for Breakout Scanner to receive daily notifications when 1167.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
JACOBIO-B (1167.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 1167.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1167.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.